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Background: Periodic monitoring of regional or institutional resistance trends of clinically 
important anaerobic bacteria is recommended, because the resistance of anaerobic 
pathogens to antimicrobial drugs and inappropriate therapy are associated with poor clini-
cal outcomes. There has been no multicenter study of clinical anaerobic isolates in Korea. 
We aimed to determine the antimicrobial resistance patterns of clinically important anaer-
obes at multiple centers in Korea. 
Methods: A total of 268 non-duplicated clinical isolates of anaerobic bacteria were col-
lected from four large medical centers in Korea in 2012. Antimicrobial susceptibility was 
tested by the agar dilution method according to the CLSI guidelines. The following antimi-
crobials were tested: piperacillin, piperacillin-tazobactam, cefoxitin, cefotetan, imipenem, 
meropenem, clindamycin, moxifloxacin, chloramphenicol, metronidazole, and tigecycline.
Results: Organisms of the Bacteroides fragilis group were highly susceptible to piperacil-
lin-tazobactam, imipenem, and meropenem, as their resistance rates to these three anti-
microbials were lower than 6%. For B. fragilis group isolates and anaerobic gram-positive 
cocci, the resistance rates to moxifloxacin were 12-25% and 11-13%, respectively. 
Among B. fragilis group organisms, the resistance rates to tigecycline were 16-17%. Two 
isolates of Finegoldia magna were non-susceptible to chloramphenicol (minimum inhibi-
tory concentrations of 16-32 mg/L). Resistance patterns were different among the differ-
ent hospitals.
Conclusions: Piperacillin-tazobactam, cefoxitin, and carbapemems are highly active 
β-lactam agents against most of the anaerobes. The resistance rates to moxifloxacin and 
tigecycline are slightly higher than those in the previous study. 
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INTRODUCTION
Antimicrobial susceptibility testing (AST) may not be necessary 
for most clinical anaerobic strains isolated from routine anaero-
bic culture. The CLSI suggests testing of isolates from serious 
infections such as bacteremia, brain abscess, endocarditis, os-
teomyelitis, and joint infection [1]. Additionally, any bacteria iso-
lated from normally sterile body sites or associated with a failure 
to respond to empirical treatment should be tested [1]. Antimi-
crobials that are potentially effective against anaerobic bacteria 
include β-lactams, combinations of β-lactams and β-lactamase 
inhibitors, metronidazole, chloramphenicol, clindamycin, mac-
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rolides, tetracyclines, and fluoroquinolones [2].
 Some anaerobic bacteria have become resistant to antimicro-
bial agents, and some can develop resistance while a patient is 
receiving therapy [3]. Moreover, there are reports that the resis-
tance of anaerobic pathogens to antimicrobials and inappropri-
ate therapy are associated with poor clinical outcomes [4, 5]. 
These findings emphasize the importance of performing sus-
ceptibility testing of organisms recovered from certain selected 
cases to guide therapeutic choices. In addition, regional sus-
ceptibility patterns play a pivotal role in the empirical treatment 
of infections caused by anaerobic bacteria. 
 In Korea, the AST for anaerobe has been regularly performed 
at Yonsei University Hospital [6, 7, 13], but there has been no 
multicenter study of clinical anaerobic isolates. We aimed to de-
termine and compare the antimicrobial resistance patterns for 
clinically important anaerobes collected from four medical cen-
ters in Korea. 
METHODS
1. Bacterial isolates
A total of 396 anaerobic isolates were prospectively collected at 
four tertiary-care hospitals (the Catholic University of Korea, CU; 
University of Ulsan College of Medicine, UU; Yonsei University 
College of Medicine, YU; Yonsei University Wonju College of 
Medicine, YW) from June to December 2012 and transported to 
YU for anaerobic identification and AST, as previously reported 
[7]. During this period, the isolates were consecutively collected 
at each hospital and recovered as one isolate per patient. An-
aerobes were isolated from blood, body fluid, and abscess 
specimens. Each isolate was identified by conventional methods 
[8], the ATB 32A system (bioMérieux, Marcy l’Etoile, France), or 
the VITEK MS (bioMérieux) matrix-assisted laser desorption ion-
ization–time-of-flight mass spectrometry system. Propionibacte-
rium acnes was excluded from the data analysis and AST. A to-
tal of 268 randomly selected isolates were used for AST: 83 
Bacteroides fragilis, 64 other B. fragilis group species, 16 Pre-
votella spp., 6 Fusobacterium spp., 12 Veillonella spp., 15 Fine-
goldia magna, 19 other gram-positive cocci, 26 Clostridium 
spp., and 27 other gram-positive bacilli.
2. Antimicrobial susceptibility testing
AST was performed by using the CLSI agar dilution method [1]. 
The medium used was Brucella agar (Becton Dickinson, Cock-
eysville, MD, USA) supplemented with 5 mg/L hemin, 1 mg/L 
vitamin K1, and 5% laked sheep blood. The antimicrobial pow-
ders used were piperacillin and tazobactam (Yuhan, Seoul, Ko-
rea), cefoxitin (Merck Sharp & Dohme, West Point, PA, USA), 
cefotetan (Daiichi Pharmaceutical, Tokyo, Japan), clindamycin 
(Korea Upjohn, Seoul, Korea), imipenem and metronidazole 
(Choong Wae, Seoul, Korea), chloramphenicol (Chong Kun 
Dang, Seoul, Korea), meropenem (Sumitomo, Tokyo, Japan), 
moxifloxacin (Bayer Korea, Seoul, Korea), and tigecycline (Wy-
eth Research, Pearl River, NY, USA). For the piperacillin-tazo-
bactam combination, a constant concentration of 4 mg/L tazo-
bactam was used. The tigecycline breakpoints of ≤  4 and ≥ 16 
mg/L, suggested by the US Food and Drug Administration, were 
used in this study [9].
 An inoculum of 105 colony forming units (CFU) was applied 
with a Steers replicator (Craft Machine Inc., Woodline, PA, 
USA), and the plates were incubated in an anaerobic chamber 
(Forma Scientific, Marietta, OH, USA) for 48 hr at 37°C. The 
minimum inhibitory concentration (MIC) of the antimicrobial 
agent was defined as the concentration at which there was a 
marked reduction in growth, such as from confluent colonies to 
a haze, <10 tiny colonies, or several normal-sized colonies [1]. 
B. fragilis ATCC 25285 and Bacteroides thetaiotaomicron ATCC 
29741 were used as the controls.
3.  Carbapenemase screening test and detection of the cfiA 
gene 
Imipenem and EDTA-sodium mercaptoacetic acid double-disk 
synergy (IEDDS) tests were carried out on Brucella agar to 
screen for carbapenemase-producing B. fragilis isolates [9]. 
The cfiA gene and its upstream insertion sequence (IS) were 
detected by PCR as previously described [10].
RESULTS
Table 1 shows the MICs of the antimicrobial agents and the re-
sistance rates of the anaerobes tested. The resistance rates of B. 
fragilis isolates and other B. fragilis group organisms to piper-
acillin were 48-58%, whereas their resistance rates to piperacil-
lin-tazobactam were 2-5%. Cefoxitin remained very active 
against B. fragilis, with only 4% of the isolates exhibiting resis-
tance; however, 13% of other B. fragilis group isolates were re-
sistant to this drug. Other B. fragilis group isolates were much 
more resistant to cefotetan, showing a 64% resistance rate. B. 
fragilis group isolates showed resistance rates of only 0-6% to 
the carbapenems, which are the most active β-lactam drugs. 
On the other hand, B. fragilis group isolates had high resistance 
rates of 52-80% to clindamycin. The resistance rates of the B. 
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Table 1. Activity of antimicrobials against 268 anaerobic bacteria isolated from four hospitals in Korea from June to December 2012
Organism (N of isolates) and 
   antimicrobial agent
Breakpoint (μg/mL)  MIC (μg/mL) Susceptibility (%)
S I R Range 50% 90% S I R
Bacteroides fragilis (83)
   Piperacillin ≤32 64 ≥128 2->256 64 >256 48 4 48
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06->128 0.5 8 96 1 2
   Cefoxitin ≤16 32 ≥64 4-128 8 32 83 13 4
   Cefotetan ≤16 32 ≥64 4->128 8 64 72 7 20
   Imipenem ≤4 8 ≥16 0.06-16 0.125 1 96 0 4
   Meropenem ≤4 8 ≥16 0.12-64 0.25 4 94 0 6
   Clindamycin ≤2 4 ≥8 ≤0.06->128 >128 >128 47 1 52
   Moxifloxacin ≤2 4 ≥8 0.25-32 0.5 8 86 2 12
   Chloramphenicol ≤8 16 ≥32 2-8 4 4 100 0 0
   Metronidazole ≤8 16 ≥32 0.125-4 1 2 100 0 0
   Tigecycline* ≤4 8 ≥16 0.5-32 4 16 65 18 17
B. fragilis group, other (64)†
   Piperacillin ≤32 64 ≥128 2->256 256 >256 38 5 58
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06->128 8 32 88 8 5
   Cefoxitin ≤16 32 ≥64 ≤1-128 16 64 50 38 13
   Cefotetan ≤16 32 ≥64 2->128 64 >128 19 17 64
   Imipenem ≤4 8 ≥16 ≤0.03-32 0.5 2 97 0 3
   Meropenem ≤4 8 ≥16 ≤0.03-8 0.25 2 98 2 0
   Clindamycin ≤2 4 ≥8 ≤0.06->128 >128 >128 13 8 80
   Moxifloxacin ≤2 4 ≥8 0.25-64 2 32 70 5 25
   Chloramphenicol ≤8 16 ≥32 2-16 4 8 98 2 0
   Metronidazole   ≤8 16 ≥32 ≤0.125-8 2 4 100 0 0
   Tigecycline ≤4 8 ≥16 ≤0.06-32 4 16 63 22 16
Prevotella spp. (16)‡
   Piperacillin ≤32 64 ≥128 ≤1-64 16 32 94 6 0
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06 ≤0.06 ≤0.06 100 0 0
   Cefoxitin ≤16 32 ≥64 ≤1-8 ≤1 4 100 0 0
   Cefotetan ≤16 32 ≥64 ≤1-16 4 16 100 0 0
   Imipenem ≤4 8 ≥16 ≤0.03-0.06 0.06 0.06 100 0 0
   Meropenem ≤4 8 ≥16 ≤0.03-0.125 0.125 0.125 100 0 0
   Clindamycin ≤2 4 ≥8 ≤0.06->128 ≤0.06 >128 63 0 38
   Moxifloxacin ≤2 4 ≥8 ≤0.06-64 2 32 56 0 44
   Chloramphenicol ≤8 16 ≥32 ≤0.5-8 2 8 100 0 0
   Metronidazole ≤8 16 ≥32 0.25-16 1 16 81 19 0
   Tigecycline ≤4 8 ≥16 0.125-4 0.25 2 100 0 0
Fusobacterium spp. (6)§
   Piperacillin ≤32 64 ≥128 ≤1-2 NA NA NA NA NA
(Continued to the next page)
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Organism (N of isolates) and 
   antimicrobial agent
Breakpoint (μg/mL)  MIC (μg/mL) Susceptibility (%)
S I R Range 50% 90% S I R
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06-1 NA NA NA NA NA
   Cefoxitin ≤16 32 ≥64 ≤1-2 NA NA NA NA NA
   Cefotetan ≤16 32 ≥64 ≤0.1 NA NA NA NA NA
   Imipenem ≤4 8 ≥16 ≤0.03-0.5 NA NA NA NA NA
   Meropenem ≤4 8 ≥16 ≤0.03 NA NA NA NA NA
   Clindamycin ≤2 4 ≥8 ≤0.06-8 NA NA NA NA NA
   Moxifloxacin ≤2 4 ≥8 0.125-4 NA NA NA NA NA
   Chloramphenicol ≤8 16 ≥32 ≤0.5-2 NA NA NA NA NA
   Metronidazole ≤8 16 ≥32 ≤0.125-0.25 NA NA NA NA NA
   Tigecycline ≤4 8 ≥16 ≤0.06-0.25 NA NA NA NA NA
Veillonella spp. (12)||
   Piperacillin ≤32 64 ≥128 ≤1-256 32 32 92 0 8
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06->128 8 16 92 0 8
   Cefoxitin   ≤16 32 ≥64 ≤1-8 ≤1 4 100 0 0
   Cefotetan ≤16 32 ≥64 ≤1 ≤1 ≤1 100 0 0
   Imipenem ≤4 8 ≥16 ≤0.03-0.5 0.25 0.5 100 0 0
   Meropenem ≤4 8 ≥16 ≤0.03 ≤0.03 ≤0.03 100 0 0
   Clindamycin ≤2 4 ≥8 ≤0.06-0.125 ≤0.06 0.125 100 0 0
   Moxifloxacin ≤2 4 ≥8 ≤0.06-16 0.25 4 83 8 8
   Chloramphenicol ≤8 16 ≥32 1-2 1 2 100 0 0
   Metronidazole ≤8 16 ≥32 ≤0.125-16 2 4 92 8 0
   Tigecycline ≤4 8 ≥16 0.25-2 1 1 100 0 0
Finegoldia magna (15)
   Piperacillin ≤32 64 ≥128 ≤1 ≤1 ≤1 100 0 0
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06-0.5 ≤0.06 0.125 100 0 0
   Cefoxitin ≤16 32 ≥64 ≤1-0.5 ≤1 ≤1 100 0 0
   Cefotetan ≤16 32 ≥64 ≤1-4 ≤1 2 100 0 0
   Imipenem ≤4 8 ≥16 ≤0.03-0.125 ≤0.03 0.06 100 0 0
   Meropenem ≤4 8 ≥16 ≤0.03-0.125 0.06 0.125 100 0 0
   Clindamycin ≤2 4 ≥8 ≤0.06->128 4 >128 47 13 40
   Moxifloxacin ≤2 4 ≥8 ≤0.06-32 0.125 16 87 0 13
   Chloramphenicol ≤8 16 ≥32 2-32 4 16 87 7 7
   Metronidazole ≤8 16 ≥32 0.25-2 0.5 1 100 0 0
   Tigecycline ≤4 8 ≥16 0.125-0.5 NA NA 100 0 0
Other gram-positive cocci (19)¶
   Piperacillin ≤32 64 ≥128 ≤1-16 ≤1 8 100 0 0
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06-16 ≤0.06 8 100 0 0
   Cefoxitin ≤16 32 ≥64 ≤1-16 ≤1 16 100 0 0
(Continued to the next page)
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Organism (N of isolates) and 
   antimicrobial agent
Breakpoint (μg/mL)  MIC (μg/mL) Susceptibility (%)
S I R Range 50% 90% S I R
   Cefotetan ≤16 32 ≥64 ≤1-128 ≤1 64 84 0 16
   Imipenem ≤4 8 ≥16 ≤0.03-2 ≤0.03 1 100 0 0
   Meropenem ≤4 8 ≥16 ≤0.03-4 ≤0.03 4 100 0 0
   Clindamycin ≤2 4 ≥8 ≤0.06-32 ≤0.06 4 89 5 5
   Moxifloxacin ≤2 4 ≥8 ≤0.06-8 0.25 8 89 0 11
   Chloramphenicol ≤8 16 ≥32 ≤0.5-4 2 4 100 0 0
   Metronidazole ≤8 16 ≥32 ≤0.125->32 0.5 >32 89 0 11
   Tigecycline ≤4 8 ≥16 ≤0.06-0.5 0.125 0.25 100 0 0
Clostridium spp. (26)**
   Piperacillin ≤32 64 ≥128 ≤1-32 ≤1 16 100 0 0
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06-32 ≤0.06 32 100 0 0
   Cefoxitin ≤16 32 ≥64 ≤1-32 ≤1 32 88 12 0
   Cefotetan ≤16 32 ≥64 ≤1->128 ≤1 4 96 0 4
   Imipenem ≤4 8 ≥16 ≤0.03-8 0.125 1 96 4 0
   Meropenem ≤4 8 ≥16 ≤0.03-8 ≤0.03 1 96 4 0
   Clindamycin ≤2 4 ≥8 ≤0.06->128 2 >128 65 12 23
   Moxifloxacin ≤2 4 ≥8 ≤0.06-32 0.5 8 85 4 12
   Chloramphenicol ≤8 16 ≥32 ≤0.5-8 2 4 100 0 0
   Metronidazole ≤8 16 ≥32 ≤0.125-4 1 2 100 0 0
   Tigecycline ≤4 8 ≥16 ≤0.06-4 0.25 4 100 0 0
Other gram-positive bacilli (27)††
   Piperacillin ≤32 64 ≥128 ≤1-32 ≤1 16 100 0 0
   Piperacillin-tazobactam ≤32 64 ≥128 ≤0.06-32 1 16 100 0 0
   Cefoxitin ≤16 32 ≥64 ≤1-16 8 16 100 0 0
   Cefotetan ≤16 32 ≥64 ≤1-128 16 64 59 7 33
   Imipenem ≤4 8 ≥16 ≤0.03-0.5 0.125 0.5 100 0 0
   Meropenem ≤4 8 ≥16 ≤0.03-0.5 0.25 0.5 100 0 0
   Clindamycin ≤2 4 ≥8 ≤0.06->128 ≤0.06 128 85 0 15
   Moxifloxacin ≤2 4 ≥8 ≤0.06-64 1 4 89 7 4
   Chloramphenicol ≤8 16 ≥32 ≤0.5-8 2 4 100 0 0
   Metronidazole ≤8 16 ≥32 0.25->32 1 >32 70 4 26
   Tigecycline ≤4 8 ≥16 ≤0.06-0.5 0.25 0.5 100 0 0
*US Food and Drug Administration breakpoints were used for tigecycline; †Bacteroides thetaiotaomicron (n=25), B. ovatus (n=8), B. vulgatus (n=8), Para-
bacteroides distasonis (n=8), B. uniformis (n=4), B. salyersae (n=3), B. caccae (n=2), B. dorei (n=1), B. nordii (n=1), B. stercoris (n=1), Odoribacter 
splanchnicus (n=1), Bacteroides sp. (n=2); ‡Prevotella bivia (n=4), P. buccae (n=3), P. intermedia (n=3), P. denticola (n=1), P. disiens (n=1), P. mela-
ninogenica (n=1), P. oralis (n=1); §Fusobacterium necrophorum (n=2), F. nucleatum (n=2), F. varium (n=1), Fusobacterium sp. (n=1); ||Veillonella par-
vula (n=10), Veillonella sp. (n=2); ¶Parvimonas micra (n=7), Peptostreptococcus anaerobius (n=4), Peptoniphilus asaccharolyticus (n=3), Peptostrepto-
coccus sp. (n=3), Streptococcus asaccharolyticus (n=2); **Clostridium perfringens (n=11), C. ramosum (n=2), C. tertium (n=2), C. baratii (n=1), C. 
clostridioforme (n=1), C. paraputrificum (n=1), Clostridium sp. (n=8); ††Actinomyces meyeri (n=2), Actinomyces naeslundii (n=1), Actinomyces neuii 
(n=1), Actinomyces sp. (n=5), Bifidobacterium sp. (n=1); Collinsella aerofaciens (n=3), Eggerthella lenta (n=10), Eubacterium lentum (n=3), Eubacteri-
um sp. (n=1).
Abbreviations: S, susceptible; I, intermediate; R, resistant; NA, not available/not applicable.
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fragilis group organisms to moxifloxacin and tigecycline were 
12-25% and 16-17%, respectively. All B. fragilis group isolates 
were susceptible to chloramphenicol and metronidazole.
 Prevotella isolates were susceptible to all antimicrobial agents 
tested, except for clindamycin (38% resistant) and moxifloxacin 
(44% resistant). The resistance rate to clindamycin was 40% 
for F. magna and 5% for other gram-positive cocci. It should be 
noted that two isolates of F. magna showed non-susceptibility to 
chloramphenicol, with MICs of 16-32 mg/L. Clostridium isolates, 
including C. perfringens, were generally susceptible to the test 
drugs, except for clindamycin (23% resistant) and moxifloxacin 
(12% resistant). Other gram-positive bacilli such as Actinomy-
ces, Bifidobacterium, Eggerthella, and Collinsella species were 
generally susceptible to the β-lactams, including piperacillin, 
but were resistant to cefoxitin (33%), metronidazole (26%), 
clindamycin (15%), and moxifloxacin (4%).
 Table 2 shows the resistance rates of the B. fragilis group and 
other B. fragilis group isolates in each hospital and reveals some 
differences in resistance patterns among the hospitals. High re-
sistance rates to cefotetan (33%) at YW and to moxifloxacin 
(22%) at CU were noted for B. fragilis isolates. Among non-B. 
fragilis isolates, the highest resistance rates were observed to-
ward piperacillin-tazobactam (13%) at YU and toward moxiflox-
acin (57%) at CU.
 Two imipenem-resistant B. fragilis isolates showed positive re-
sults on the IEDDS test, whereas two imipenem-resistant B. the-
taiotaomicron isolates did not. The cfiA gene and its upstream 
IS elements were detected in two imipenem-resistant B. fragilis 
isolates. 
DISCUSSION
This study is the first report of the antimicrobial susceptibility 
patterns of anaerobic clinical isolates collected from four institu-
tions in Korea. Some results in this study (from YU) have been 
previously published [7], and these results were reanalyzed to-
gether with the data from the other three hospitals. Among the 
anaerobes identified in clinical specimens, isolates from the B. 
fragilis group are the most commonly encountered and are also 
more virulent and more resistant to antimicrobial agents than 
the other anaerobes [10]. Piperacillin was the most active of the 
ureidopenicillins against the B. fragilis group, with the organ-
isms showing 38-48% resistance rates in this study. Piperacillin-
tazobactam was active against nearly all strains of the B. fragilis 
group, with only 2-5% resistance rates in this study, in accor-
dance with the less than 7% resistance in previous studies [12-
14].
 The poor activity of clindamycin against the B. fragilis group 
is recognized worldwide and has been reported in several stud-
ies [15-17]. High rates of resistance to clindamycin among B. 
fragilis group isolates have also been reported in Korea [10, 14], 
and the recent anaerobic isolates tested in this study showed 
resistance rates of 52-80%. Moxifloxacin was recently intro-
duced for the treatment of skin and soft tissue infections [18]. 
The resistance rates (12-25%) to moxifloxacin of B. fragilis 
group organisms in this study were slightly higher than the 11-
18% rates reported in 2010 in Korea [14] but lower than the 
34-55% rates in US hospitals [1]. 
 Jacobus et al. [19] reported that the geometric mean MICs of 
tigecycline for Parabacteroides distasonis were significantly 
higher than those for other Bacteroides species. Karlowsky et al. 
[16] noted that 14% of B. fragilis isolates and 31% of B. the-
taiotaomicron isolates were resistant to tigecycline, compared 
with 5% of B. fragilis isolates and 3-7% of other B. fragilis group 
isolates in the study by Snydman et al. [15]. Our data showed 
tigecycline resistance rates of 16-17% for the B. fragilis group 
isolates.
 Overall, Prevotella and Fusobacterium isolates were more 
susceptible to the antimicrobials than B. fragilis group organ-
isms. The resistance rates to moxifloxacin were as low as 24% 
and 36% for Prevotella isolates in Belgium [18] and USA [20], 
respectively, whereas 44% of Prevotella isolates were resistant 
Table 2. Comparison of resistance rates of Bacteroides fragilis and 
other Bacteroides spp. isolates by hospital
Antimicrobial agent
Resistance rates (%) of B. fragilis/resistance rates 
(%) of other B. fragilis group isolates
CU (23/14)* YU (22/24) UU (17/16) YW (21/10)
Piperacillin 52/57 23/79 53/50 67/20
Piperacillin-tazobactam 0/0 0/13 6/0 0/0 
Cefoxitin 0/0 5/17 12/25 0/0
Cefotetan 22/57 9/75 18/63 33/50
Imipenem 0/0 0/8 18/0 0/0
Meropenem 4/0 5/0 18/0 0/0
Clindamycin 48/98 41/92 59/75 62/50
Moxifloxacin 22/57 5/17 12/13 10/20
Chloramphenicol 0/0 0/0 0/0 0/0
Metronidazole 0/0 0/0 0/0 0/0 
*Number of B. fragilis/other B. fragilis group isolates.
Abbreviations: CU, the Catholic University of Korea; YU, Yonsei University 
College of Medicine; UU, University of Ulsan College of Medicine; YW, Yon-
sei University Wonju College of Medicine. 
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to moxifloxacin in this study. Papaparaskevas et al. [21] re-
ported that moxifloxacin resistance was prevalent among Pre-
votella and Bacteroides species in Greece. Moreover, species 
variation was noted, with the highest non-susceptible rates be-
ing detected among Prevotella oralis (90%) and Prevotella bivia 
(80%). The discovery in this study of two F. magna isolates that 
were non-susceptible to chloramphenicol is interesting, since 
chloramphenicol-resistant anaerobic gram-positive cocci have 
not been reported.
 In this study, there were some differences in the geographical 
patterns of resistance, and even differences in resistance pat-
terns among the different hospitals in a single city, perhaps due 
in part to variability in the patterns of prescribing drugs. The 
CLSI recommends that hospitals conduct at least one annual 
AST surveillance to elucidate local patterns of resistance. Over-
all, isolates from UU B. fragilis were more resistant to cefoxitin 
(12% vs. 5%), imipenem (18% vs. 0%), and meropenem (18% 
vs. 5%) (drugs highly active against group organisms) than 
those from the other hospitals. The difference in resistance rates 
among hospitals may be important when selecting appropriate 
antimicrobial treatment options, although susceptibility testing is 
not generally performed for individual patient isolates.
 Carbapenem resistance is usually mediated by metallo-β-
lactamase, which is encoded by the cfiA gene in the presence 
of IS elements that activate the gene [22]. In the present study, 
two imipenem-resistant B. fragilis isolates carried the cfiA gene 
with upstream IS elements. 
 In conclusion, piperacillin-tazobactam, cefoxitin, imipenem, 
meropenem, metronidazole, and chloramphenicol remain ac-
tive against most anaerobic isolates. The 2012 rates of resis-
tance to moxifloxacin and tigecycline for B. fragilis group isolates 
were slightly higher than those reported in 2010 [14]. There 
were some differences in resistance patterns among the differ-
ent hospitals. Continuous monitoring is necessary to detect 
changes in resistance patterns at regional centers and hospitals.
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